His appointment is part of GSK’s broader strategy to put more weight behind its consumer brand portfolio, which includes Lucozade, Sensodyne and Panadol.
GSK is expected to name another senior comms professional who will report into McGibbon.
McGibbon will report into GSK’s president of global comms Phil Thomas.
Earlier this year GSK announced it is to sell off more than 19 of its smaller brands such as controversial weight management drug Alli and sleep remedy Nytol in a bid to refocus the company on faster growing brands.
McGibbon joins GSK in September. At IHG, McGibbon is senior vice president of global corporate affairs.